دورية أكاديمية
أعرض في EDS

Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain.

التفاصيل البيبلوغرافية
العنوان: Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain.
المؤلفون: Kessoku T; Department of Palliative Medicine, International University of Health and Welfare Narita Hospital, Narita, JPN.; Department of Gastroenterology, International University of Health and Welfare School of Medicine, Narita, JPN.; Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, JPN., Higashibata T; Department of Palliative and Supportive Care, University of Tsukuba Hospital, Tsukuba, JPN., Morioka Y; Department of Medical Affairs, Shionogi & Co. Ltd., Osaka, JPN., Naya N; Department of Medical Affairs, Shionogi & Co. Ltd., Osaka, JPN., Koretaka Y; Department of Data Science, Shionogi & Co. Ltd., Osaka, JPN., Ichikawa Y; Department of Oncology, Yokohama City University School of Medicine, Yokohama, JPN., Hisanaga T; Department of Palliative Medicine, Tsukuba Medical Center Hospital, Tsukuba, JPN., Nakajima A; Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, JPN.
المصدر: Cureus [Cureus] 2024 Mar 10; Vol. 16 (3), pp. e55925. Date of Electronic Publication: 2024 Mar 10 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Introduction Naldemedine and magnesium oxide are common first-line early laxative medications used in the real-world scenario in Japan, for patients with cancer pain who receive opioid prescriptions, as per a nationwide hospital claims database study. However, the real-world prescription patterns and associated outcomes are unknown. Methods In this retrospective, cohort study using the Medical Data Vision (MDV) database (January 2018 to December 2020), data were collected from eligible patients (who had a long-term prescription of strong opioids, for >30 days) in Japan with naldemedine or magnesium oxide as the first-line laxative prescription, for a long-term opioid prescription for cancer pain with ≥6 months post-opioid observation period. A laxative prescription within three days after the opioid prescription date was termed an "early" prescription. The composite incidence of dose increase or addition/change of laxatives at three months after the start of the opioid prescription was the primary endpoint after adjusting baseline characteristics between the treatment arms by propensity score matching. Results After propensity score matching, 1717 and 544 patients who were prescribed naldemedine and magnesium oxide each were included in the early prescription and non-early prescription groups, respectively. Even after matching, the incidence of death was not adjusted enough and was significantly higher in the naldemedine arm than in the magnesium oxide arm in the non-early group but comparable in the early group. The incidence of addition, change, or dose increase was significantly higher in the naldemedine arm than in the magnesium oxide arm of the early prescription group (hazard ratio (95% confidence interval), 1.08 (1.00, 1.17); p =0.0402); the incidence was comparable between the arms of the non-early group. Conclusion These findings may provide valuable insights into real-world clinical treatment patterns and preliminary evidence for the selection of first-line medications to mitigate opioid-induced constipation in Japanese patients with cancer pain.
Competing Interests: The authors have declared financial relationships, which are detailed in the next section.
(Copyright © 2024, Kessoku et al.)
References: J Opioid Manag. 2009 May-Jun;5(3):137-44. (PMID: 19662923)
Nutrients. 2021 Jan 28;13(2):. (PMID: 33525523)
Support Care Cancer. 2022 Jul;30(7):5831-5836. (PMID: 35355120)
Support Care Cancer. 2022 May;30(5):3943-3954. (PMID: 35044484)
J Palliat Med. 2022 Jul;25(7):1095-1114. (PMID: 35363057)
Cancers (Basel). 2022 Apr 24;14(9):. (PMID: 35565243)
Clin J Pain. 2012 Jun;28(5):373-81. (PMID: 22156893)
Pain Med. 2017 Oct 01;18(10):1837-1863. (PMID: 28034973)
Gastroenterology. 2019 Jan;156(1):218-226. (PMID: 30340754)
Pain Res Treat. 2018 Jul 10;2018:5704627. (PMID: 30112202)
Scand J Pain. 2016 Apr;11:104-110. (PMID: 28850447)
Nihon Hoshasen Gijutsu Gakkai Zasshi. 2017;73(5):397-402. (PMID: 28529254)
Clinicoecon Outcomes Res. 2014 May 23;6:269-81. (PMID: 24904217)
J Pharm Pharmacol. 2016 Sep;68(9):1214-21. (PMID: 27364763)
J Clin Oncol. 2017 Dec 1;35(34):3859-3866. (PMID: 28968171)
PLoS One. 2022 Dec 9;17(12):e0278823. (PMID: 36490241)
Pharmacotherapy. 2022 Mar;42(3):241-249. (PMID: 34967450)
Support Care Cancer. 2020 Mar;28(3):1083-1088. (PMID: 31183560)
J Neurogastroenterol Motil. 2019 Oct 30;25(4):563-575. (PMID: 31587548)
Life Sci. 2020 Sep 15;257:118048. (PMID: 32622946)
Medicina (Kaunas). 2021 Nov 11;57(11):. (PMID: 34833451)
Ann Palliat Med. 2012 Jul;1(2):121-9. (PMID: 25841472)
Drugs. 1991 Mar;41(3):326-44. (PMID: 1711441)
Pain Ther. 2023 Aug;12(4):993-1003. (PMID: 37195398)
Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. (PMID: 11755892)
Gastroenterol Res Pract. 2014;2014:141737. (PMID: 24883055)
Pain Med. 2009 Jan;10(1):35-42. (PMID: 18721170)
فهرسة مساهمة: Keywords: analgesics; cancer; constipation; database; japan; magnesium oxide; naldemedine; opioids
تواريخ الأحداث: Date Created: 20240411 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11004843
DOI: 10.7759/cureus.55925
PMID: 38601408
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.55925